Daratumumab SC Clinical Trials
2 recruitingDrug
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Lymphoma, Primary Effusion
National Cancer Institute (NCI)28 enrolled1 locationNCT05907759
Recruiting
Phase 2
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Multiple Myeloma
Carl Ola Landgren, MD, PhD50 enrolled1 locationNCT06100237